Comparative Pharmacology
Head-to-head clinical analysis: QLOSI versus REGORAFENIB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QLOSI versus REGORAFENIB.
QLOSI vs REGORAFENIB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
QLOSI is a monoclonal antibody that binds to and inhibits the activity of interleukin-5 (IL-5), thereby reducing eosinophil production and survival.
Regorafenib is a multikinase inhibitor that targets various angiogenic (VEGFR1-3, TIE2), stromal (PDGFR-β, FGFR), and oncogenic kinases (KIT, RET, RAF). It inhibits tumor angiogenesis, growth, and metastasis.
100 mg orally once daily.
160 mg orally once daily on days 1-21 of a 28-day cycle until disease progression or unacceptable toxicity.
None Documented
None Documented
Terminal elimination half-life is approximately 9 hours; clinical context: allows twice-daily dosing in patients with normal renal function.
Clinical Note
moderateRegorafenib + Digoxin
"Regorafenib may increase the bradycardic activities of Digoxin."
Clinical Note
moderateRegorafenib + Digitoxin
"Regorafenib may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateRegorafenib + Deslanoside
"Regorafenib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateRegorafenib + Acetyldigitoxin
"Regorafenib may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life is 14–28 hours (mean approximately 20 hours), supporting twice-daily dosing with a 3-weeks-on/1-week-off schedule to allow washout and reduce toxicity accumulation.
Primarily renal excretion of unchanged drug (approximately 85%), with the remainder eliminated via biliary/fecal routes (15%).
Primarily fecal (approximately 71% of the radiolabeled dose) with renal excretion accounting for 19% (mostly as metabolites). Unchanged regorafenib is minimal in urine.
Category C
Category D/X
Kinase Inhibitor
Kinase Inhibitor